Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Titel:
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Auteur:
Nuciforo, P.G. Aura, C. Holmes, E. Prudkin, L. Jimenez, J. Martinez, P. Ameels, H. de la Peña, L. Ellis, C. Eidtmann, H. Piccart-Gebhart, M.J. Scaltriti, M. Baselga, J.